BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
With Obamacare premium hikes, more people opting for no coverage or cheaper plans- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- Which Instax Camera Would it be a good idea for you to Purchase?
- 10 Asian Countries Perfect for Solo Female Travelers
- Remain Cool and Solid: Top Summer Food sources for 2024
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- 5 Pizza Fixings That Characterize Your Character
